A Longitudinal Comparison of Arm Morbidity in Stage I-II Breast Cancer Patients Treated with Sentinel Lymph Node Biopsy, Sentinel Lymph Node Biopsy Followed by Completion Lymph Node Dissection, or Axillary Lymph Node Dissection

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2010 Mar 12

PMID 20221902

Citations 31

Authors

Jan J Kootstra

Josette E H M Hoekstra-Weebers

Johan S Rietman

Jakob De Vries

Peter C Baas

Jan H B Geertzen

Harald J Hoekstra

Affiliations

Soon will be listed here.

Abstract

Background: Long-term shoulder and arm function following sentinel lymph node biopsy (SLNB) may surpass that following complete axillary lymph node dissection (CLND) or axillary lymph node dissection (ALND). We objectively examined the morbidity and compared outcomes after SLNB, SLNB + CLND, and ALND in stage I/II breast cancer patients.

Materials And Methods: Breast cancer patients who had SLNB (n = 51), SLNB + CLND (n = 55), and ALND (n = 65) were physically examined 1 day before surgery (T0), and after 6 (T1), 26 (T2), 52 (T3), and 104 (T4) weeks. Differences in 8 parameters between the affected and unaffected arms were calculated. General linear models were computed to examine time, group, and interaction effects.

Results: All outcomes changed significantly, mostly nonlinearly, over time (T0-T4). Between T1 and T4, limitations decreased in abduction (all groups); anteflexion, abduction-exorotation, abduction strength (SLNB + CLND, ALND); flexion strength (SLNB + CLND); and arm volume (SLNB, SLNB + CLND). At T4, limitations in anteflexion (SLNB, ALND), abduction (SLNB + CLND, ALND), exorotation (ALND), abduction-exorotation (all groups), and volume (SLNB + CLND, ALND) increased significantly compared with T0. The SLNB group showed an advantage in anteflexion, abduction, abduction-exorotation, and volume. Groups changed significantly but differently over time in anteflexion, abduction, abduction/exorotation, abduction strength, flexion strength, and volume. Effect sizes varied from 0.19 to 0.00.

Conclusion: Initial declines in range of motion and strength were followed by recovery, although not always to presurgery levels. Range of motion and volume outcomes were better for SLNB than ALND, but not strength. SLNB surpassed SLNB + CLND in 2 of the range of motion variables. The clinical relevance of these results is negligible.

Citing Articles

A nomogram model for predicting the risk of axillary lymph node metastasis in patients with early breast cancer and cN0 status.

Zhang Z, Jiang Q, Wang J, Yang X Oncol Lett. 2024; 28(2):345.

PMID: 38872855 PMC: 11170244. DOI: 10.3892/ol.2024.14478.

Comparison of Intraoperative Imprint Cytology versus Frozen Section for Sentinel Lymph Node Evaluation in Breast Cancer. A study along with Systematic Review and Meta-analysis of literature.

Ahuja S, Yadav P, Fattahi-Darghlou M, Zaheer S Asian Pac J Cancer Prev. 2024; 25(4):1113-1119.

PMID: 38679970 PMC: 11162742. DOI: 10.31557/APJCP.2024.25.4.1113.

Immediate Lymphatic Reconstruction with Vascularized Omentum Lymph Node Transplant: Reducing the Risk of Both Painful Contracture and Lymphedema.

Brown S, Kokosis G, Graziano F, Haran O, Smith-Montes E, Zivanovic O Plast Reconstr Surg Glob Open. 2024; 12(4):e5747.

PMID: 38645629 PMC: 11029981. DOI: 10.1097/GOX.0000000000005747.

Upper Limb Morbidity in Newly Diagnosed Individuals After Unilateral Surgery for Breast Cancer: Baseline Results from the AMBER Cohort Study.

McNeely M, Courneya K, Al Onazi M, Wharton S, Wang Q, Dickau L Ann Surg Oncol. 2023; 30(13):8389-8397.

PMID: 37755568 DOI: 10.1245/s10434-023-14316-3.

Can inflammatory indices predict sentinel lymph node status in patients with early-stage breast cancer?.

Balbaloglu H, Tasdoven I, Karadeniz Cakmak G Medicine (Baltimore). 2023; 102(33):e34808.

PMID: 37603529 PMC: 10443763. DOI: 10.1097/MD.0000000000034808.

References

Kootstra J, Hoekstra-Weebers J, Rietman H, de Vries J, Baas P, Geertzen J . Quality of life after sentinel lymph node biopsy or axillary lymph node dissection in stage I/II breast cancer patients: a prospective longitudinal study. Ann Surg Oncol. 2008; 15(9):2533-41. PMC: 2518082. DOI: 10.1245/s10434-008-9996-9. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Mansel R, Fallowfield L, Kissin M, Goyal A, Newcombe R, Dixon J . Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98(9):599-609. DOI: 10.1093/jnci/djj158. View

Goyal A, Newcombe R, Chhabra A, Mansel R . Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND. Ann Surg Oncol. 2007; 15(1):262-7. DOI: 10.1245/s10434-007-9593-3. View

Madsen A, Haugaard K, Soerensen J, Bokmand S, Friis E, Holtveg H . Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group. Breast. 2007; 17(2):138-47. DOI: 10.1016/j.breast.2007.08.006. View

Ronka R, von Smitten K, Tasmuth T, Leidenius M . One-year morbidity after sentinel node biopsy and breast surgery. Breast. 2005; 14(1):28-36. DOI: 10.1016/j.breast.2004.09.010. View

Burak W, Hollenbeck S, Zervos E, Hock K, Kemp L, Young D . Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg. 2002; 183(1):23-7. DOI: 10.1016/s0002-9610(01)00848-0. View

Rutgers E, Jansen L, Nieweg O, de Vries J, Schraffordt Koops H, Kroon B . Technique of sentinel node biopsy in breast cancer. Eur J Surg Oncol. 1998; 24(4):316-9. DOI: 10.1016/s0748-7983(98)80014-0. View

Rietman J, Dijkstra P, Geertzen J, Baas P, de Vries J, Dolsma W . Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer. Ann Surg Oncol. 2004; 11(11):1018-24. DOI: 10.1245/ASO.2004.03.512. View

10.

Swenson K, Nissen M, Ceronsky C, Swenson L, Lee M, Tuttle T . Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol. 2002; 9(8):745-53. DOI: 10.1007/BF02574496. View

11.

Mathiowetz V, Weber K, Volland G, Kashman N . Reliability and validity of grip and pinch strength evaluations. J Hand Surg Am. 1984; 9(2):222-6. DOI: 10.1016/s0363-5023(84)80146-x. View

12.

Leidenius M, Leppanen E, Krogerus L, von Smitten K . Motion restriction and axillary web syndrome after sentinel node biopsy and axillary clearance in breast cancer. Am J Surg. 2003; 185(2):127-30. DOI: 10.1016/s0002-9610(02)01214-x. View

13.

Leidenius M, Leivonen M, Vironen J, von Smitten K . The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance. J Surg Oncol. 2005; 92(1):23-31. DOI: 10.1002/jso.20373. View

14.

Purushotham A, Upponi S, Klevesath M, Bobrow L, Millar K, Myles J . Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005; 23(19):4312-21. DOI: 10.1200/JCO.2005.03.228. View

15.

Wilke L, McCall L, Posther K, Whitworth P, Reintgen D, Leitch A . Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006; 13(4):491-500. DOI: 10.1245/ASO.2006.05.013. View

16.

Haid A, Kuehn T, Konstantiniuk P, Koberle-Wuhrer R, Knauer M, Kreienberg R . Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol. 2002; 28(7):705-10. DOI: 10.1053/ejso.2002.1327. View

17.

Langer I, Guller U, Berclaz G, Koechli O, Schaer G, Fehr M . Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007; 245(3):452-61. PMC: 1877006. DOI: 10.1097/01.sla.0000245472.47748.ec. View

18.

Krag D, Anderson S, Julian T, Brown A, Harlow S, Ashikaga T . Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007; 8(10):881-8. DOI: 10.1016/S1470-2045(07)70278-4. View

19.

Peintinger F, Reitsamer R, Stranzl H, Ralph G . Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer. 2003; 89(4):648-52. PMC: 2376906. DOI: 10.1038/sj.bjc.6601150. View

20.

Liu C, Guo Y, Shi J, Sheng Y . Late morbidity associated with a tumour-negative sentinel lymph node biopsy in primary breast cancer patients: a systematic review. Eur J Cancer. 2009; 45(9):1560-8. DOI: 10.1016/j.ejca.2009.02.012. View